{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T22:12:50Z","timestamp":1785795170843,"version":"3.56.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T00:00:00Z","timestamp":1665619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["203930\/B\/16\/Z"],"award-info":[{"award-number":["203930\/B\/16\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010414","name":"Health Research Board","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010414","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Midlife Type 2 Diabetes Mellitus (T2DM) is associated with an increased risk of Alzheimer Disease (AD) in later life, with altered inflammatory responses postulated as key pathological drivers. Previous studies have demonstrated increased responsiveness to NLR family pyrin domain containing 3 (NLRP3) inflammasome agonists, both in individuals with untreated T2DM in addition to those with established AD. We hypothesised that peripheral NLRP3 inflammasome responses may be altered during the early stages of T2DM-related cognitive dysfunction. Here, we assessed the relationship between NLPR3 responses in peripheral blood mononuclear cells (including to A\u03b2-42, the putative pathogenic protein in AD) and neuropsychological performance in uncomplicated midlife T2DM to identify early signatures of immune dysregulation which may predispose to later cognitive decline. We recruited a cross-sectional cohort of middle-aged adults with uncomplicated T2DM and matched Healthy Controls (HCs) for comprehensive neuropsychological assessment and <jats:italic>in vitro<\/jats:italic> PBMC responses to a range of NLRP3 agonists were assessed. T2DM was associated with subtle decrements on neuropsychological tests of delayed memory and executive function (both p&amp;lt;0.05). Overall, there were no differences between T2DM and HCs in immune responses induced by NLRP3 agonists. Further, we observed no relationship between the subtle neuropsychological decrements observed in T2DM and PBMC responsiveness to NLRP3 agonists. Our data suggests that peripheral NLRP3 inflammasome response dysregulation may not play a role in the early stages of cognitive dysfunction in midlife T2DM. Further longitudinal studies are warranted to examine the contribution of peripheral NLRP3 responses towards disease pathology and as cognitive decline accelerates in T2DM.<\/jats:p>","DOI":"10.3389\/fimmu.2022.1021351","type":"journal-article","created":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T08:46:15Z","timestamp":1665650775000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Neuropsychological decrements in midlife type-2 diabetes are not associated with peripheral NLRP3 inflammasome responsiveness"],"prefix":"10.3389","volume":"13","author":[{"given":"Adam H.","family":"Dyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Batten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conor","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liam","family":"Townsend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conor P.","family":"Woods","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desmond","family":"O\u2019Neill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Gibney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean P.","family":"Kennelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nollaig M.","family":"Bourke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41574-018-0048-7","article-title":"Cognitive decline and dementia in diabetes mellitus: Mechanisms and clinical implications","volume":"14","author":"Biessels","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.53.9.1937","article-title":"Diabetes mellitus and the risk of dementia: The Rotterdam study","volume":"53","author":"Ott","year":"1999","journal-title":"Neurology"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2017.1658","article-title":"Associations between midlife vascular risk factors and 25-year incident dementia in the atherosclerosis risk in communities (ARIC) cohort","volume":"74","author":"Gottesman","year":"2017","journal-title":"JAMA Neurol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.4001","article-title":"Association between age at diabetes onset and subsequent risk of dementia","volume":"325","author":"Barbiellini Amidei","year":"2021","journal-title":"Jama"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-018-0070-3","article-title":"Lifestyle interventions to prevent cognitive impairment, dementia and Alzheimer disease","volume":"14","author":"Kivipelto","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60461-5","article-title":"A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): A randomised controlled trial","volume":"385","author":"Ngandu","year":"2015","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcz053","article-title":"Non-pharmacological interventions for cognition in patients with type 2 diabetes mellitus: a systematic review","volume":"113","author":"Dyer","year":"2020","journal-title":"Qjm"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2010.228","article-title":"Cognitive function, dementia and type 2 diabetes mellitus in the elderly","volume":"7","author":"Strachan","year":"2011","journal-title":"Nat Rev Endocrinol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0213-9","article-title":"Targeting innate immune mediators in type 1 and type 2 diabetes","volume":"19","author":"Donath","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/nri2925","article-title":"Type 2 diabetes as an inflammatory disease","volume":"11","author":"Donath","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4275","article-title":"Targeting inflammation in the treatment of type 2 diabetes: Time to start","volume":"13","author":"Donath","year":"2014","journal-title":"Nat Rev Drug Discovery"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3806","article-title":"A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases","volume":"21","author":"Coll","year":"2015","journal-title":"Nat Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/ni.1935","article-title":"Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1\u03b2 in type 2 diabetes","volume":"11","author":"Masters","year":"2010","journal-title":"Nat Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"194","DOI":"10.2337\/db12-0420","article-title":"Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes","volume":"62","author":"Lee","year":"2013","journal-title":"Diabetes"},{"key":"B15","doi-asserted-by":"publisher","first-page":"15056","DOI":"10.1038\/nrdp.2015.56","article-title":"Alzheimer's disease","volume":"1","author":"Masters","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"B16","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/imcb.12301","article-title":"The role of innate immune responses and neuroinflammation in amyloid accumulation and progression of alzheimer's disease","volume":"98","author":"Webers","year":"2020","journal-title":"Immunol Cell Biol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2013.24","article-title":"Love and death: Microglia, NLRP3 and the alzheimer's brain","volume":"23","author":"Goldmann","year":"2013","journal-title":"Cell Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-017-1831-7","article-title":"Neuroinflammatory responses in alzheimer's disease","volume":"125","author":"Dansokho","year":"2018","journal-title":"J Neural Transm (Vienna)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/nature11729","article-title":"NLRP3 is activated in alzheimer's disease and contributes to pathology in APP\/PS1 mice","volume":"493","author":"Heneka","year":"2013","journal-title":"Nature"},{"key":"B20","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jneuroim.2018.11.010","article-title":"Inhibitors of NF-\u03baB and P2X7\/NLRP3\/Caspase 1 pathway in microglia: Novel therapeutic opportunities in neuroinflammation induced early-stage alzheimer's disease","volume":"326","author":"Thawkar","year":"2019","journal-title":"J Neuroimmunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2009680117","article-title":"The NLRP3 inflammasome inhibitor OLT1177 rescues cognitive impairment in a mouse model of alzheimer's disease","volume":"117","author":"Lonnemann","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2016.12.014","article-title":"Inhibiting the NLRP3 inflammasome with MCC950 promotes non-phlogistic clearance of amyloid-\u03b2 and cognitive function in APP\/PS1 mice","volume":"61","author":"Dempsey","year":"2017","journal-title":"Brain Behav Immun"},{"key":"B23","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13024-016-0088-1","article-title":"The NLRP3 and NLRP1 inflammasomes are activated in alzheimer's disease","volume":"11","author":"Saresella","year":"2016","journal-title":"Mol Neurodegener"},{"key":"B24","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jneuroim.2018.02.007","article-title":"A shift to glycolysis accompanies the inflammatory changes in PBMCs from individuals with an IQ-discrepant memory","volume":"317","author":"Wolfe","year":"2018","journal-title":"J Neuroimmunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0063194","article-title":"Identifying early inflammatory changes in monocyte-derived macrophages from a population with IQ-discrepant episodic memory","volume":"8","author":"Downer","year":"2013","journal-title":"PloS One"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.psyneuen.2018.06.014","article-title":"Increased plasma interleukin-1\u03b2 level is associated with memory deficits in type 2 diabetic patients with mild cognitive impairment","volume":"96","author":"Tian","year":"2018","journal-title":"Psychoneuroendocrinology"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.2337\/db09-1163","article-title":"Association between raised inflammatory markers and cognitive decline in elderly people with type 2 diabetes: the Edinburgh type 2 diabetes study","volume":"59","author":"Marioni","year":"2010","journal-title":"Diabetes"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2020.605878","article-title":"Peripheral inflammation and cognitive performance in middle-aged adults with and without type 2 diabetes: Results from the ENBIND study","volume":"12","author":"Dyer","year":"2020","journal-title":"Front Aging Neurosci"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/dme.14412","article-title":"Cognitive performance in midlife type 2 diabetes: results from the ENBIND study","volume":"38","author":"Dyer","year":"2021","journal-title":"Diabetes Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.12195","article-title":"Normative values of cognitive and physical function in older adults: findings from the Irish longitudinal study on ageing","author":"Kenny","year":"2013","journal-title":"J Am Geriatr Soc"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1017\/S1355617716000722","article-title":"Computerized cognitive tests are associated with biomarkers of alzheimer's disease in cognitively normal individuals 10 years prior","volume":"22","author":"Soldan","year":"2016","journal-title":"J Int Neuropsychol Soc"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3932(98)00036-0","article-title":"Test\/re-test reliability of the CANTAB and ISPOCD neuropsychological batteries: Theoretical and practical issues. Cambridge neuropsychological test automated battery. international study of post-operative cognitive dysfunction","volume":"36","author":"Lowe","year":"1998","journal-title":"Neuropsychologia"},{"key":"B33","doi-asserted-by":"publisher","first-page":"196","DOI":"10.2174\/1871530315666150316124019","article-title":"Metformin and inflammation: Its potential beyond glucose-lowering effect","volume":"15","author":"Saisho","year":"2015","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"B34","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12950-016-0142-3","article-title":"Effects of metformin on blood and urine pro-inflammatory mediators in patients with type 2 diabetes","volume":"13","author":"Chen","year":"2016","journal-title":"J Inflammation (Lond)"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.116.308445","article-title":"Anti-inflammatory effects of metformin irrespective of diabetes status","volume":"119","author":"Cameron","year":"2016","journal-title":"Circ Res"},{"key":"B36","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/bph.15508","article-title":"Protective properties of GLP-1 and associated peptide hormones in neurodegenerative disorders","volume":"179","author":"H\u00f6lscher","year":"2022","journal-title":"Br J Pharmacol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-013-3145-0","article-title":"Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus","volume":"57","author":"Hogan","year":"2014","journal-title":"Diabetologia"},{"key":"B38","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1186\/s13063-020-04608-4","article-title":"Correction to: Evaluating the effects of the novel GLP-1 analogue liraglutide in alzheimer's disease: study protocol for a randomised controlled trial (ELAD study)","volume":"21","author":"Femminella","year":"2020","journal-title":"Trials"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-021-05634-w","article-title":"Higher baseline inflammatory marker levels predict greater cognitive decline in older people with type 2 diabetes: year 10 follow-up of the Edinburgh type 2 diabetes study","volume":"65","author":"Sluiman","year":"2022","journal-title":"Diabetologia"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1021351\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T08:46:19Z","timestamp":1665650779000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1021351\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,13]]},"references-count":39,"alternative-id":["10.3389\/fimmu.2022.1021351"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1021351","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,13]]},"article-number":"1021351"}}